The Recall Desk
LowFDA (Devices)·Z-0504-2016·Announced 2015-12-30

Ameditech iCup DX 12 Panel Drug Test Recall for Reduced Reactivity

Ameditech is recalling iCup DX 12 Panel drug tests because they may show reduced reactivity for two specific benzodiazepine compounds.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as unlikely to cause adverse health consequences, typically resulting in a score of 1 or 2.

Plain-English summary

Ameditech Inc is recalling 9,566 kits of the iCup DX 12 Panel w/ Adulterant (Item No. I-DXA-1127-023). The recall is due to reduced reactivity for up to two of the nineteen benzodiazepine compounds listed in the product insert. The specific compounds affected are Clonazepam and Chlordiazepoxide.

The affected products were distributed nationwide. The recall is classified as Class III by the FDA, indicating that use of the product is not likely to cause adverse health consequences. The issue involves the accuracy of the test results for specific benzodiazepine substances rather than a direct physical hazard to the user.

The recalled product

Product
iCup DX 12 Panel w/ Adulterant, Item No. I-DXA-1127-023
Manufacturer
Ameditech Inc
Affected units
9,566

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 59 recalled by Ameditech Inc under a single FDA (Devices) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 59 products in this recall →